Default company panoramic image
Logo small

RJSBio, Inc.

RJSBio is developing “tethered addressed” non-peptide small-molecules for the treatment of cancer and inflammatory conditions.

  • Stage Prototype Ready
  • Industry Biotechnology
  • Location Seattle, WA, US
  • Currency USD
  • Founded February 2009
  • Employees 8
  • Website

Company Summary

A cancer drug’s journey to its intended target is a key component to its ultimate success or failure. At RJSBio we define the path of a cancer drug to, and within, a cancer cell using fully-synthetic drug conjugates.

Our modular small-molecule approach leads to efficient uptake of toxic conjugates specifically by cancer cells. Our design minimizes unwanted uptake of these drugs by normal cells, where harmful side effects are manifested.


  • Default avatar
    Stephen M. McCraith, PhD

    2009-Current Founder/CSO, RJS Biologics, LLC. Seattle, WA

    2006-2009 Senior Scientist, Ameritech Inc., Millcreek, WA
    Development of Diagnostic Tests for HIV and Cancer.

    2006-2006 Senior Scientist, Allozyne Inc.
    Inventor of AZ01, Allozyne's lead MS biological currently in Phase I/II.

    2004-2006 Senior Scientist I, Albany Molecular Research, Bothell WA
    Assay development/screening a 500,000 member natural product library.

  • Default avatar
    6 Members - List available upon request
    Scientific Advisors,

    RJS Bio has a team of talented and renowned scientific advisers that it prefers to not disclose on this public website. These advisers bring a wealth of talent in the areas of organic chemistry, in silico drug design, pharmacology, in vivo cancer models as well as experience in small molecule and biological development.


  • Default avatar
    Jeffrey Oster, Ph.D.,J.D

Previous Investors

  • Default avatar
    RJS Biologics has been personally funded while in stealth mode.
    Default avatar
    We are now seeking outside funding through investments and SBIR funding.